These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
132 related articles for article (PubMed ID: 9987699)
1. Long-term systemic exposure of orlistat, a lipase inhibitor, and its metabolites in obese patients. Zhi J; Mulligan TE; Hauptman JB J Clin Pharmacol; 1999 Jan; 39(1):41-6. PubMed ID: 9987699 [TBL] [Abstract][Full Text] [Related]
2. Review of limited systemic absorption of orlistat, a lipase inhibitor, in healthy human volunteers. Zhi J; Melia AT; Eggers H; Joly R; Patel IH J Clin Pharmacol; 1995 Nov; 35(11):1103-8. PubMed ID: 8626884 [TBL] [Abstract][Full Text] [Related]
3. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group. Sjöström L; Rissanen A; Andersen T; Boldrin M; Golay A; Koppeschaar HP; Krempf M Lancet; 1998 Jul; 352(9123):167-72. PubMed ID: 9683204 [TBL] [Abstract][Full Text] [Related]
4. Orlistat, a gastrointestinal lipase inhibitor, in therapy of obesity with concomitant hyperlipidemia. Micić D; Ivković-Lazar T; Dragojević R; Jorga J; Stokić E; Hajduković Z Med Pregl; 1999; 52(9-10):323-33. PubMed ID: 10624380 [TBL] [Abstract][Full Text] [Related]
5. Orlistat maintains biliary lipid composition and hepatobiliary function in obese subjects undergoing moderate weight loss. Trouillot TE; Pace DG; McKinley C; Cockey L; Zhi J; Häeussler J; Guerciolini R; Showalter R; Everson GT Am J Gastroenterol; 2001 Jun; 96(6):1888-94. PubMed ID: 11421247 [TBL] [Abstract][Full Text] [Related]
6. Orlistat: in the prevention and treatment of type 2 diabetes mellitus. Keating GM; Jarvis B Drugs; 2001; 61(14):2107-19; discussion 2120-1. PubMed ID: 11735640 [TBL] [Abstract][Full Text] [Related]
7. Metabolic profiles of minimally absorbed orlistat in obese/overweight volunteers. Zhi J; Melia AT; Funk C; Viger-Chougnet A; Hopfgartner G; Lausecker B; Wang K; Fulton JS; Gabriel L; Mulligan TE J Clin Pharmacol; 1996 Nov; 36(11):1006-11. PubMed ID: 8973989 [TBL] [Abstract][Full Text] [Related]
8. Orlistat, a lipase inhibitor, for weight maintenance after conventional dieting: a 1-y study. Hill JO; Hauptman J; Anderson JW; Fujioka K; O'Neil PM; Smith DK; Zavoral JH; Aronne LJ Am J Clin Nutr; 1999 Jun; 69(6):1108-16. PubMed ID: 10357727 [TBL] [Abstract][Full Text] [Related]
9. Efficacy and tolerability of orlistat in the treatment of obesity: a 6-month dose-ranging study. Orlistat Dose-Ranging Study Group. Van Gaal LF; Broom JI; Enzi G; Toplak H Eur J Clin Pharmacol; 1998 Apr; 54(2):125-32. PubMed ID: 9626916 [TBL] [Abstract][Full Text] [Related]
10. The interaction of the lipase inhibitor orlistat with ethanol in healthy volunteers. Melia AT; Zhi J; Zelasko R; Hartmann D; Güzelhan C; Guerciolini R; Odink J Eur J Clin Pharmacol; 1998; 54(9-10):773-7. PubMed ID: 9923583 [TBL] [Abstract][Full Text] [Related]
11. [Pharmacological therapy of obesity]. Pagotto U; Vanuzzo D; Vicennati V; Pasquali R G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):83S-93S. PubMed ID: 18773755 [TBL] [Abstract][Full Text] [Related]
12. The effect of orlistat, an inhibitor of dietary fat absorption, on the pharmacokinetics of beta-carotene in healthy volunteers. Zhi J; Melia AT; Koss-Twardy SG; Arora S; Patel IH J Clin Pharmacol; 1996 Feb; 36(2):152-9. PubMed ID: 8852391 [TBL] [Abstract][Full Text] [Related]
13. A one-year trial to assess the value of orlistat in the management of obesity. James WP; Avenell A; Broom J; Whitehead J Int J Obes Relat Metab Disord; 1997 Jun; 21 Suppl 3():S24-30. PubMed ID: 9225173 [TBL] [Abstract][Full Text] [Related]
14. The effect of short-term (21-day) orlistat treatment on the physiologic balance of six selected macrominerals and microminerals in obese adolescents. Zhi J; Moore R; Kanitra L J Am Coll Nutr; 2003 Oct; 22(5):357-62. PubMed ID: 14559927 [TBL] [Abstract][Full Text] [Related]
15. The effects of orlistat on weight and on serum lipids in obese patients with hypercholesterolemia: a randomized, double-blind, placebo-controlled, multicentre study. Muls E; Kolanowski J; Scheen A; Van Gaal L; Int J Obes Relat Metab Disord; 2001 Nov; 25(11):1713-21. PubMed ID: 11753595 [TBL] [Abstract][Full Text] [Related]
16. Orlistat (Ro 18-0647), a lipase inhibitor, in the treatment of human obesity: a multiple dose study. Drent ML; Larsson I; William-Olsson T; Quaade F; Czubayko F; von Bergmann K; Strobel W; Sjöström L; van der Veen EA Int J Obes Relat Metab Disord; 1995 Apr; 19(4):221-6. PubMed ID: 7627244 [TBL] [Abstract][Full Text] [Related]
17. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. Davidson MH; Hauptman J; DiGirolamo M; Foreyt JP; Halsted CH; Heber D; Heimburger DC; Lucas CP; Robbins DC; Chung J; Heymsfield SB JAMA; 1999 Jan; 281(3):235-42. PubMed ID: 9918478 [TBL] [Abstract][Full Text] [Related]
18. Long-term effects of lipase inhibition by orlistat on gastric emptying and orocecal transit time of a solid meal. Kocełak P; Zahorska-Markiewicz B; Jonderko K; Olszanecka-Glinianowicz M; Zak-Gołab A; Holecki M; Kamińska M; Szymszal M J Gastroenterol; 2008; 43(8):609-17. PubMed ID: 18709483 [TBL] [Abstract][Full Text] [Related]
19. Reduction of dietary fat absorption by the novel gastrointestinal lipase inhibitor cetilistat in healthy volunteers. Bryson A; de la Motte S; Dunk C Br J Clin Pharmacol; 2009 Mar; 67(3):309-15. PubMed ID: 19220279 [TBL] [Abstract][Full Text] [Related]
20. Short-term orlistat treatment does not affect mineral balance and bone turnover in obese men. Pace DG; Blotner S; Guerciolini R J Nutr; 2001 Jun; 131(6):1694-9. PubMed ID: 11385055 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]